Stockscreener 앱 받기
28.00
21.21%
4.90
전일 마감가:
$23.10
열려 있는:
$25.17
하루 거래량:
2.51M
Relative Volume:
2.01
시가총액:
$205.24M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-2.4867
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
+48.70%
1개월 성능:
+76.54%
6개월 성능:
+113.58%
1년 성능:
-95.18%
1일 변동 폭
$25.00
$30.20
1주일 범위
$18.50
$30.20
52주 변동 폭
$7.31
$672.00
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
28.00 | 129.51M | 0 | -121.02M | -114.09M | -11.26 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results - Benzinga
Stocks To Watch: Tonix Pharmaceuticals Sees RS Rating Jump To 89 - inkl
Tonix Pharmaceuticals Recruits Seasoned Industry Atty As GC - Law360
Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive - Investing.com India
Tonix Pharmaceuticals Appoints Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - citybiz
Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EV - GuruFocus
Tonix Pharma Appoints New General Counsel and EVP - TipRanks
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, - GlobeNewswire
Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision - Stock Titan
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Tonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats - GuruFocus
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Tonix Pharma earnings beat by $22.84, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewswire
Tonix Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals reports annual meeting results - Investing.com Australia
Tonix showcases promising gastric cancer data at AACR Conference - Proactive financial news
(TNXP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Tonix Pharmaceuticals: Looking Past FDA Approval To Challenging Commercial Opportunity - Seeking Alpha
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700 - citybuzz -
Tonix Pharma Unveils Promising Cancer Treatment Data - TipRanks
Tonix Pharmaceuticals Presented Preclinical Data on Gastric - GlobeNewswire
Tonix Pharmaceuticals (TNXP) Showcases Promising Cancer Research at AACR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Canc - GuruFocus
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting - The Manila Times
Tonix Pharmaceuticals and Makana partner to advance research with Anti-Rejection therapy - Proactive Investors
Groundbreaking Cancer Therapy Shows Promise: Tonix's New Combination Treatment Activates Cancer-Killing Cells - Stock Titan
Tonix culls cocaine intoxication trial amid enrollment woes - Fierce Biotech
Tonix Pharmaceuticals Holding CorpDiscontinued Enrollment And Terminated Phase 2 Catalyst StudySEC Filing - marketscreener.com
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data - citybuzz -
Tonix reports promising results for mpox vaccine TNX-801 By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (TNXP) Unveils Promising Results for Single-Dose Mpox Vaccine | TNXP Stock News - GuruFocus
Tonix reports promising results for mpox vaccine TNX-801 - Investing.com
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine T - GuruFocus
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 - The Manila Times
Tonix Pharmaceuticals Presented Data on Potential Mpox - GlobeNewswire
Tonix Pharma Presents Promising Vaccine Data at Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Falls Despite Market Upturn - GuruFocus
Tonix Pharmaceuticals (TNXP) to Present at World Vaccine Congres - GuruFocus
When the Price of (TNXP) Talks, People Listen - news.stocktradersdaily.com
Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025 - marketscreener.com
Tonix Pharmaceuticals Announces Oral Presentation and Panel - GlobeNewswire
Major Breakthrough: Tonix Unveils Single-Dose Mpox Vaccine Data at Leading Global Conference - Stock Titan
Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? - MSN
Tonix and Makana partner on xenotransplantation research By Investing.com - Investing.com India
Tonix Pharmaceuticals and Makana Therapeutics Announce Collabora - GuruFocus
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):